Aerovate Therapeutics Inc Company Overview
About Aerovate Therapeutics Inc
Aerovate Therapeutics (NASDAQ: AVTE) is dedicated to advancing treatments for rare cardiopulmonary diseases. With a focus on innovation, the company aims to transform the standard of care for patients with limited options. At the heart of its pipeline is AV-101, an inhaled dry powder formulation currently in clinical trials for the treatment of pulmonary arterial hypertension (PAH). Aerovate is committed to improving patient outcomes through cutting-edge research and strategic collaborations, driving promising therapies from development to commercialization. Recognizing the critical need for advancements in its field, Aerovate's objectives include accelerating drug development timelines, expanding its therapeutic offerings, and enhancing the quality of life for those affected by rare cardiopulmonary disorders.
Snapshot
Operations
Produtos e/ou serviços de Aerovate Therapeutics Inc
- AV-101: An inhaled dry powder formulation of imatinib in Phase 2b/3 clinical trials focused on treating pulmonary arterial hypertension (PAH) by addressing the underlying causes of the disease.
- Advancing research in small molecules: Focus on developing additional small molecule therapies to complement AV-101, targeting unmet needs in rare cardiopulmonary and other related diseases.
- Strategic partnerships: Establishing collaborations with academic institutions and biopharmaceutical companies to enhance drug development capabilities and pipeline diversification.
- Clinical program expansion: Plans to explore further clinical programs beyond PAH, capitalizing on existing expertise in pulmonary and cardiovascular therapeutic areas.
- Regulatory engagement: Active engagement with regulatory bodies to streamline development timelines and ensure compliance with necessary approval processes.
- Intellectual property management: Maintaining a robust portfolio of patents and trademarks to protect proprietary technology and innovation, ensuring competitive advantage in the marketplace.
equipe executiva do Aerovate Therapeutics Inc
- Mr. Timothy P. Noyes M.B.A.CEO & Director
- Mr. George A. EldridgeCFO & Treasurer
- Dr. Benjamin T. Dake Ph.D.Founder, President, COO & Secretary
- Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.SChief Scientific Officer
- Mr. Hunter Gillies M.D.Chief Medical Officer
- Ms. Donna DeaHead of Regulatory Affairs
- Ms. Susan FischerExecutive Vice President of Development Operations
- Mr. Stephen K. YuSenior Vice President of Quality
- Dr. Sanjeev KhindriExecutive Vice President of Clinical Development
- Dr. Cheryl Lassen BSc., M.D., MBBChSenior Vice President of Clinical Development